AI Engines For more Details: Perplexity Kagi Labs You
Fungal Skin Infections: Naftifine hydrochloride is effective against a variety of fungal organisms responsible for causing skin infections. It works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, leading to disruption of fungal cell growth and ultimately fungal cell death.
Athlete's Foot (Tinea Pedis): Naftifine is commonly used to treat athlete's foot, a fungal infection that typically affects the spaces between the toes. It helps alleviate symptoms such as itching, burning, redness, and scaling associated with this condition. Treatment with naftifine typically involves applying the medication topically to the affected area once or twice daily for several weeks.
Jock Itch (Tinea Cruris): Naftifine hydrochloride is also effective in treating jock itch, a fungal infection that affects the groin and inner thighs. It helps relieve symptoms such as itching, redness, and rash in the affected area. Topical application of naftifine is usually recommended for a specified duration to achieve complete resolution of the infection.
Ringworm (Tinea Corporis): Ringworm is a fungal infection that can affect any part of the body, causing a circular rash with raised edges. Naftifine hydrochloride can be used to treat ringworm infections by applying the medication directly to the affected skin. It helps eliminate the fungus responsible for the infection and promotes healing of the affected area.
Efficacy: Clinical studies have demonstrated the efficacy of naftifine hydrochloride in the treatment of various fungal skin infections, with a high cure rate observed in many cases. It is often preferred due to its broad spectrum of activity against dermatophyte fungi and its low potential for systemic side effects.
Safety Profile: Naftifine hydrochloride is generally well-tolerated when used as directed. Most adverse effects are mild and transient, with common side effects including skin irritation, burning, itching, and redness at the application site. Serious systemic side effects are rare due to the topical route of administration.
Compliance and Adherence: The success of naftifine therapy depends on patient compliance with the prescribed treatment regimen. It is important for patients to use the medication as directed, applying it consistently and for the full duration recommended by their healthcare provider, even if symptoms improve before the infection is completely cleared.
Prevention: In addition to treating existing fungal infections, naftifine hydrochloride can also be used prophylactically to prevent recurrence of infections in individuals prone to fungal skin conditions. Maintaining good hygiene practices, keeping the skin clean and dry, and avoiding sharing personal items such as towels and clothing can also help prevent fungal infections.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.9 | 0.3 | 2 |
Age-Related Macular Degeneration and Glaucoma | 0.2 | 0.2 | 0 |
Allergic Rhinitis (Hay Fever) | 0.2 | 0.2 | |
Allergies | 0.7 | 1.3 | -0.86 |
Allergy to milk products | 0.2 | 0.2 | 0 |
Alopecia (Hair Loss) | 0.6 | 0.6 | |
Alzheimer's disease | 0.7 | 1.5 | -1.14 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.2 | 1 | 1.2 |
Ankylosing spondylitis | 0.6 | 0.6 | 0 |
Anorexia Nervosa | 0.2 | 1 | -4 |
Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
Asthma | 0.2 | 1.4 | -6 |
Atherosclerosis | 0.2 | 1.3 | -5.5 |
Atrial fibrillation | 1.2 | 0.2 | 5 |
Autism | 3.6 | 3.5 | 0.03 |
Barrett esophagus cancer | 0 | 0 | |
Bipolar Disorder | 0.4 | 0.7 | -0.75 |
Brain Trauma | 0 | 0.2 | 0 |
Carcinoma | 0.8 | 0.6 | 0.33 |
Celiac Disease | 0.2 | 1.3 | -5.5 |
Cerebral Palsy | 0.5 | 0.5 | 0 |
Chronic Fatigue Syndrome | 1.6 | 1.5 | 0.07 |
Chronic Kidney Disease | 0.3 | 1.1 | -2.67 |
Chronic Lyme | 0.2 | -0.2 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 0.7 | -2.5 |
Chronic Urticaria (Hives) | 0 | 0.8 | 0 |
Coagulation / Micro clot triggering bacteria | 0.2 | 0.5 | -1.5 |
Colorectal Cancer | 0.7 | 0.2 | 2.5 |
Constipation | 0.4 | 0.3 | 0.33 |
Coronary artery disease | 0.4 | 0.2 | 1 |
COVID-19 | 3 | 5.4 | -0.8 |
Crohn's Disease | 1.5 | 2.8 | -0.87 |
cystic fibrosis | 0.2 | -0.2 | |
deep vein thrombosis | 0.5 | -0.5 | |
Depression | 3.6 | 3.1 | 0.16 |
Dermatomyositis | 0 | 0 | |
Eczema | 0.1 | -0.1 | |
Endometriosis | 0.4 | 0.7 | -0.75 |
Epilepsy | 0.5 | 1.6 | -2.2 |
Fibromyalgia | 1.4 | 0.3 | 3.67 |
Functional constipation / chronic idiopathic constipation | 1.1 | 0.4 | 1.75 |
gallstone disease (gsd) | 0.4 | 0.2 | 1 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | -0.2 | |
Generalized anxiety disorder | 0.1 | 0.2 | -1 |
Glioblastoma | 0 | 0 | |
Gout | 0.2 | -0.2 | |
Graves' disease | 0.2 | 0.3 | -0.5 |
Halitosis | 0 | 0 | |
Hashimoto's thyroiditis | 0.7 | 0.7 | |
Hidradenitis Suppurativa | 0 | 0 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.7 | 0.2 | 2.5 |
hypercholesterolemia (High Cholesterol) | 0.1 | 0.8 | -7 |
hyperglycemia | 1.4 | -1.4 | |
Hyperlipidemia (High Blood Fats) | 0.4 | 0 | 0 |
hypersomnia | 0.1 | -0.1 | |
hypertension (High Blood Pressure | 0.9 | 1 | -0.11 |
Hypothyroidism | 0.3 | -0.3 | |
Hypoxia | 0.6 | 0.6 | |
IgA nephropathy (IgAN) | 0.7 | -0.7 | |
Inflammatory Bowel Disease | 1.1 | 4.1 | -2.73 |
Insomnia | 0.1 | 0.6 | -5 |
Intelligence | 0.2 | 0.2 | |
Intracranial aneurysms | 0.4 | 0 | 0 |
Irritable Bowel Syndrome | 1.2 | 1.5 | -0.25 |
Liver Cirrhosis | 1.4 | 1 | 0.4 |
Long COVID | 3.5 | 2.8 | 0.25 |
Low bone mineral density | 0.7 | -0.7 | |
Lung Cancer | 1.1 | -1.1 | |
ME/CFS with IBS | 0.9 | 0.5 | 0.8 |
ME/CFS without IBS | 0.5 | 0.5 | 0 |
Metabolic Syndrome | 1.6 | 2.2 | -0.38 |
Mood Disorders | 4.8 | 3.2 | 0.5 |
multiple chemical sensitivity [MCS] | 0.5 | 0.1 | 4 |
Multiple Sclerosis | 2.3 | 2.2 | 0.05 |
Multiple system atrophy (MSA) | 1.4 | 0.3 | 3.67 |
Neuropathy (all types) | 0.5 | 0.5 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.1 | 2.2 | -21 |
Obesity | 1.6 | 2 | -0.25 |
obsessive-compulsive disorder | 1.5 | 1.3 | 0.15 |
Osteoarthritis | 0.9 | 0.2 | 3.5 |
Osteoporosis | 0.3 | 0.9 | -2 |
pancreatic cancer | 0.2 | 0.2 | |
Parkinson's Disease | 1.7 | 1.6 | 0.06 |
Polycystic ovary syndrome | 0.4 | 1.2 | -2 |
Postural orthostatic tachycardia syndrome | 0.2 | -0.2 | |
Premenstrual dysphoric disorder | 0.1 | 0.2 | -1 |
primary biliary cholangitis | 0 | 0 | |
Psoriasis | 0.8 | 1.8 | -1.25 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.8 | 0.5 | 2.6 |
Rosacea | 0.2 | 0.2 | 0 |
Schizophrenia | 2 | 0.6 | 2.33 |
scoliosis | 0.2 | 0.9 | -3.5 |
Sjögren syndrome | 0.4 | 0.4 | 0 |
Sleep Apnea | 0.4 | 0.5 | -0.25 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0 | 0 | |
Stress / posttraumatic stress disorder | 0.8 | 1.4 | -0.75 |
Systemic Lupus Erythematosus | 0.7 | 1 | -0.43 |
Tic Disorder | 0.3 | 0 | 0 |
Tourette syndrome | 0.4 | 0.4 | |
Type 1 Diabetes | 0.4 | 0.6 | -0.5 |
Type 2 Diabetes | 1.6 | 2.1 | -0.31 |
Ulcerative colitis | 0.1 | 1.9 | -18 |
Unhealthy Ageing | 1.5 | 1.2 | 0.25 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.